Viking Therapeutics, Inc.
NASDAQ•VKTX
CEO: Dr. Brian Lian Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-04-28
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Contact Information
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, 92121, United States
858-704-4660
Market Cap
$4.13B
P/E (TTM)
-11.3
17.4
Dividend Yield
--
52W High
$43.15
52W Low
$18.92
52W Range
Rank63Top 94.0%
1.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$1.38+0.00%
4-Quarter Trend
FCF
-$85.29M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
VK2735 Obesity Trials Advance Initiated VANQUISH Phase 3 subcutaneous studies (June 2025); oral Phase 2 showed 12.2% weight loss.
R&D Spending Jumps 239% Research and development expenses reached $345.0M in 2025, up 239.4% from $101.6M in 2024.
Strong Cash Position Maintained Cash and investments totaled $705.7M as of December 31, 2025, funding operations into Q1 2027.
Risk Factors
Clinical Stage Continued Losses Accumulated deficit reached $847.5M by year-end 2025; company expects significant future operating losses.
Dependence on Ligand Agreement Business growth heavily relies on maintaining exclusive rights under the critical Master License Agreement with Ligand.
Litigation Risks Remain Active Legal proceedings against Ascletis Defendants continue, including appeals filed in September 2025 regarding trade secrets.
Outlook
VK2735 Phase 3 Execution Expect completion of VANQUISH Phase 3 subcutaneous trials (78 weeks) in 2027 for obesity/diabetes indications.
VK2735 Oral Phase 3 Planning Expect initiation of Phase 3 oral dosing studies in the third quarter of 2026 based on positive Phase 2 results.
DACRA Program IND Filing Plan to file Investigational New Drug (IND) application for the novel DACRA program in Q1 2026.
Peer Comparison
Revenue (TTM)
$1.07B
$521.31M
$510.17M
Gross Margin (Latest Quarter)
2763.6%
143.6%
111.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| KYMR | $6.66B | -22.1 | -29.1% | 4.7% |
| PRAX | $6.28B | -22.0 | -58.7% | 0.0% |
| CGON | $5.46B | -31.0 | -22.9% | 0.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 21, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data